Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports

Abstract Background The use of immune checkpoint inhibitor (ICI) therapy is becoming a standard of care for several cancers. Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) or its ligand (PD-L1) cause a broad spectrum of autoimmune...

Full description

Bibliographic Details
Main Authors: Marco Zezza, Christophe Kosinski, Carine Mekoguem, Laura Marino, Haithem Chtioui, Nelly Pitteloud, Faiza Lamine
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Endocrine Disorders
Subjects:
Immune checkpoint inhibitor
Autoimmune adverse events
Endocrinopathies
Type 1 diabetes
Online Access:https://doi.org/10.1186/s12902-019-0467-z

Internet

https://doi.org/10.1186/s12902-019-0467-z

Similar Items